Evolution of WHO Influenza Antiviral Stockpile for Pandemic Preparedness and Response

Strategic Insights -

A recent research study has highlighted the evolution of the World Health Organization's (WHO) influenza antiviral stockpile and its role in ensuring rapid access and use of antivirals during pandemics, particularly in low- and middle-income countries. The study noted that the SARS outbreak and influenza A(H5N1) infections in 2003-2004 prompted the establishment of a global influenza antiviral stockpile by the WHO. This stockpile enabled rapid distribution to 72 countries during the 2009 A(H1N1) pandemic. To improve access in low- and middle-income countries, the WHO added antivirals to the WHO Model List of Essential Medicines and included them in the Prequalification Programme.

The 2011 Pandemic Influenza Preparedness Framework refined strategies for equitable access and rapid response, and lessons from the COVID-19 pandemic led to the establishment of a new WHO-led mechanism-the Interim Medical Countermeasures Network (i-MCM-net)-which supports integrated supply chains, real-time data sharing, research and development, and equitable access.

The WHO continues to emphasize equity and global solidarity, highlighting the need for accessible, effective, and affordable antivirals alongside vaccines to protect vulnerable populations and mitigate the impact of future pandemics.

Key Takeaways:

  • The WHO established a global influenza antiviral stockpile following the SARS outbreak and influenza A(H5N1) infections in 2003-2004, enabling rapid distribution to 72 countries during the 2009 A(H1N1) pandemic.
  • The WHO added antivirals to the WHO Model List of Essential Medicines and included them in the Prequalification Programme to improve access in low- and middle-income countries.
  • The 2011 Pandemic Influenza Preparedness Framework refined strategies for equitable access and rapid response during pandemics.
  • The Interim Medical Countermeasures Network (i-MCM-net) supports integrated supply chains, real-time data sharing, research and development, and equitable access to antivirals during pandemics.
  • The WHO emphasizes the need for accessible, effective, and affordable antivirals alongside vaccines to protect vulnerable populations and mitigate the impact of future pandemics.
  • The WHO continues to prioritize equity and global solidarity in responding to pandemics.

Statistics:

  • 72 countries received antiviral stockpiles during the 2009 A(H1N1) pandemic.
  • The WHO Model List of Essential Medicines includes antivirals to ensure accessible treatment in low- and middle-income countries.
  • 2011: The Pandemic Influenza Preparedness Framework was refined to enhance equitable access and rapid response.
  • The Interim Medical Countermeasures Network (i-MCM-net) supports integrated supply chains, real-time data sharing, research and development, and equitable access to antivirals during pandemics.

Sources:

  • "Evolution of WHO Influenza Antiviral Stockpile: Rapid Access and Use in Low- and Middle-Income Countries for Pandemic Preparedness and Response." The Journal of Infectious Diseases, 2025;232.
  • World Health Organization (WHO)
  • The Journal of Infectious Diseases
  • Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA